A fully integrated specialty pharmaceutical company with industry-leading transdermal expertise
Noven Pharmaceuticals, Inc. is a dynamic specialty pharmaceutical company engaged in the research, development, manufacture, marketing, and sale of prescription pharmaceutical products. We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery.
With over 130 years of combined experience, the Noven Executive Team is comprised of a diverse group of leaders working towards a common goal of benefiting patients around the world through innovative transdermal drug technologies.
Noven's history began in 1987 in Miami, Florida, with the mission to develop differentiated prescription transdermal drug delivery systems (patches) to benefit patients across a range of therapeutic conditions. Today, Noven is the US platform for Hisamitsu, the world's largest patch manufacturer, with fully integrated R&D, clinical, manufacturing, and sales functions offering prescription products in the areas of women's health and mental health.
We are a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., the world’s largest manufacturer of transdermal patches. We serve as Hisamitsu’s platform in US prescription pharmaceuticals, helping Hisamitsu bring the benefits of patch therapy to patients around the world.
Noven Pharmaceuticals, Inc. and its Noven Therapeutics subsidiary are mutually committed to maintaining the highest standards of professionalism, ethics, integrity, and compliance across their respective businesses, activities, and interactions.